Cellectar Biosciences presented data at SNMMI on study of iopofosine I 131

Cellectar Biosciences announced it presented data at the Society of Nuclear Medicine and Molecular Imaging, SNMMI, Annual Meeting from 64 evaluable, relapsed, or refractory multiple myeloma patients in which iopofosine I 131 demonstrated an overall response rate of 28%, a clinical benefit rate of 70% and a disease control rate of 92%. The company’s chief operating officer, Jarrod Longcor, presented data on a total of 72 post-5th line MM patients, of which 64 were evaluable and with 57% being classified as high risk. The oral presentation highlighted data demonstrating the outcomes from two dose levels across these highly refractory patients. The focus was on 28 patients that received the optimal dose of greater than60 mCi total administered dose. These patients were predominately either post-BCMA immunotherapy, triple-class refractory or quad-class refractory. Key data in the patients receiving greater than60 mCi TAD included: Overall response rate of 32%, Clinical benefit rate of 75%, Disease control rate of 85.7%. Key data in patient subsets that were highly refractory and received greater than60 mCi TAD included: 46% ORR in triple-class refractory patients, median PFS of 3.4 months; 50% ORR in quad-class refractory patients, PFS evaluation ongoing; 50% ORR in post BCMA relapsed or refractory patients, median PFS of 3.3 months. The most commonly observed treatment emergent adverse events were consistent with those previously reported: cytopenias including Grade 3 or 4 thrombocytopenia, anemia, neutropenia, and decreased white blood cell count.